Anti-CD20 monoclonal antibody
Ofatumumab
Brand names: Kesimpta, Arzerra
Adult dose
Dose: MS: 20mg SC at weeks 0, 1, 2, 4, then 20mg every 4 weeks
Route: SC
Frequency: monthly (after loading)
Clinical pearls
- Relapsing-remitting MS — self-administered SC
- Screen HBV; vaccinate before treatment
Contraindications
- Active severe infection
- Active HBV
- Hypersensitivity
Side effects
- Injection site reactions
- URTI
- Hypogammaglobulinaemia
- Infection (incl. HBV reactivation, PML rare)
Interactions
- Live vaccines
- Other immunosuppressants
Monitoring
- IgG
- Infection signs
Reference: BNF; NICE TA699; SmPC; https://bnf.nice.org.uk/drugs/ofatumumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Drugs
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS